News

New Study Published in JACC Clinical EP Validates that Cardiologs’ AI Eliminates Nearly Two-Thirds of False Positives in Remote Monitoring for AFib

10.02.2021

PARIS and BOSTON, Feb. 10, 2021 /PRNewswire/ — Cardiologs, a global leader in artificial intelligence (AI) cardiology diagnostics, today announced that results of a clinical study the company conducted in collaboration with Valley Health System have been published in the Journal of the American College of Cardiology Clinical Electrophysiology (“JACC Clinical EP”). The findings show that Cardiologs’ AI-based ECG analysis solution significantly reduces the rate of false positive atrial fibrillation (AFib) detection in remote cardiac monitoring of patients with implantable loop recorders (ILRs).

Cardiologs and Valley Health tracked a cohort of 425 patients who received an ILR for known AFib or cryptogenic stroke. All applicable ECG readings were uploaded into Cardiologs’ cloud-based solution for analysis by the company’s deep learning algorithm. In total, 1,500 AFib episodes were evaluated. Overall, the research showed Cardiologs’ AI model eliminated the incidence of false-positives by as much as 66% and had a positive predictive value (PPV) as high as 75% – demonstrating the solution is highly effective at identifying true AFib episodes.

“The high false positive rate of AFib detected by ILRs has created a significant clinical burden. Since ILRs transmit data daily, these false positives are one of the Achilles heels of remote cardiac monitoring. This study validates that Cardiologs’ advanced AI can filter 2/3 of false positive AF episodes, which should improve clinical efficiency,” said Dr. Suneet Mittal, Director of Electrophysiology and Snyder Center for Comprehensive Atrial Fibrillation at Valley Health System, and lead investigator of the study.

According to the American Heart Association, more than 2.7 million Americans are living with AFib, and that number continues to grow. ILRs play a critical role in the management of these patients. Devices with wireless capabilities are programmed to automatically transmit ECG data to a secure website for review by cardiology staff. However, the large volume of recordings can present challenges – in particular, the substantial number of false-positives alerts that electrophysiologists must review to avoid misdiagnosis and potential errors in clinical management.

“The need for reliable and efficient remote patient management is stronger than ever before and will only increase in the future. Publication of our successful trial results in JACC EP further validates the considerable promise of our solution for the clinical community. We have demonstrated that we can offer an extremely reliable solution that will reduce the clinical burden of managing ILR patients remotely,” said Yann Fleureau, Cardiologs’ Co-Founder and CEO.

A complete copy of the study can be found here: AI Filter Improves Positive Predictive Value of Atrial Fibrillation Detection by an Implantable Loop Recorder

About Cardiologs
Cardiologs is a medical technology company committed to transforming cardiac diagnostics using medical-grade artificial intelligence and cloud technology.  Developed in partnership with leading physicians, the Cardiologs ECG Analysis Solution empowers clinicians worldwide to deliver expert cardiac care faster and more efficiently.  CE-Marked and FDA cleared for detection of 14 cardiac arrhythmias, the Cardiologs ECG Analysis Solution is built on a growing database of more than 1.4 million ECG recordings and is supported by a number of clinical publications.

Media Contact:
Andrea LePain
eMedia Junction 
andrea@emediajunction.com 
617-275-8112

Rick Anderson and Mark Toland Join Cardiologs’ Board of Directors

07.10.2020

PARIS and BOSTON, Oct. 7, 2020 /PRNewswire/ — Cardiologs, a global leader in artificial intelligence (AI) for cardiac diagnostics, announced today that it has appointed two veteran medical device industry executives to the company’s board of directors – Rick Anderson and Mark Toland.

“We are delighted and grateful that two proven leaders of this caliber share our passion and belief in the value of Cardiologs’ AI platform and its tremendous potential to continue to transform and democratize cardiac care,” said Yann Fleureau, Cardiologs’ Co-Founder and CEO. “These are two visionaries who are revered for commercializing technologies around the world. Harnessing their strategic insight and vast knowledge, we are now well positioned to scale our platform and write the next chapter of growth for the benefit of patients around the globe.”

Anderson brings more than three decades of experience as an executive, investor and board member for emerging growth and market leading healthcare technology companies, with a focus on cardiology. He currently serves as Chairman of Revival Healthcare Capital, a sustainable, high impact investment platform that specializes in medical devices and diagnostics. Prior to founding Revival, Anderson held roles as Managing Director at PTV Healthcare Capital and multiple executive leadership positions, including as Worldwide Franchise Chairman, Cordis Corporation and Company Group Chairman at Johnson & Johnson.

“Deep learning introduces extraordinary opportunities to elevate clinical practice, potentially in multiple specialties, and to benefit patients,” said Anderson. “I see Cardiologs as a platform capable of going beyond the product offering they have today in cardiology. There are a broad range of capabilities resident in the company and its technology – whether they be in remote monitoring or electrophysiology or beyond. I think Cardiologs has a great opportunity to leverage its platform on an even larger scale.”

Toland is the former CEO of Corindus Vascular Robotics, where he helped transform the company from an emerging startup with a struggling early generation product into the global leader in interventional robotics with indications for coronary, peripheral vascular, and neurovascular interventional procedures. In 2019, Siemens Healthineers paid $1.1 billion to acquire the company. Prior to Corindus, Toland served as Senior Vice President of Boston Scientific, leading BSC’s growth and market-innovation initiatives across all business units. He recently joined BioStar Capital, a value-add investment firm focused on transformational medical device technologies that serve unmet patient needs in cardiovascular and orthopedic medicine.

“To me, this is a lifesaving journey,” said Toland. “Throughout my career, I’ve seen firsthand the healthcare ecosystem’s need for deep learning AI capabilities to support decision-making. If we can quantitatively analyze massive volumes of information and decipher exactly where patients are in their disease state – and where they need to go next – it’s going to have a profound impact on patients, society and how we deliver healthcare. Bringing AI into the fold will enable physicians to make better decisions, faster and more efficiently, with greater accuracy. That shift will allow us to improve access to care and save lives.”

Anderson and Toland were selected following an international search led by Roger Brooks, President and CEO of RBrooks Group. They join Cardiologs following a successful Series A fundraising round led by Alven Capital.

About Cardiologs
Cardiologs is a medical technology company committed to transforming cardiac diagnostics using medical-grade artificial intelligence and cloud technology. Developed in partnership with leading physicians, the Cardiologs ECG Analysis Solution empowers clinicians worldwide to deliver expert cardiac care faster and more efficiently. CE-Marked and FDA cleared for detection of 14 cardiac arrhythmias, the Cardiologs ECG Analysis Solution is built on a growing database of more than 4 million ECG recordings and is supported by a number of clinical publications.

Media Contact:

Andrea LePain
eMedia Junction
andrea@emediajunction.com
617-275-8112

Cardiologs Partners with MicroPort CRM to Distribute its AI-based Cardiac Diagnostics Solution in France

01.09.2020

The ECG Holter agreement marks the launch of Cardiologs’ AI-based cloud technology business operations in Europe to detect cardiac rhythm disorders.

BOSTON, Sept. 1, 2020 /PRNewswire/ — Cardiologs, a global leader in artificial intelligence (AI) cardiology diagnostics, today announced an exclusive distribution agreement in France with MicroPort CRM, for the reselling of its cloud analysis solution for Holter ECGs. MicroPort CRM is a worldwide leader in the conception and distribution of implantable devices for the treatment of heart rhythm disorders and the leader in France of Holter ECG monitoring devices and software. This agreement marks the official launch, at a large scale, of Cardiologs’ European business operations.

As a pioneer in AI-based healthcare, Cardiologs was the first company to obtain a CE mark for an AI-based medical device. Cardiologs’ medical-grade AI automatically identifies cardiac rhythm disorders with a high level of accuracy and in a timely manner, cutting diagnosis and analysis time in half. Thanks to its secure cloud solution, which is General Data Protection Regulations (GDPR) compliant and hosted onto a “Hébergeur de Données de Santé” (HDS)-certified server, the analysis is available in real-time, from everywhere, by all professionals involved in a patient’s care, thus simplifying the logistics of ECG diagnostics.

Cardiologs is device-agnostic and can interpret data from a broad range of cardiac monitoring devices, a choice aligned with the evolution of health tech towards greater openness and interoperability. Already in use in several healthcare facilities, Cardiologs’ solution has been immediately endorsed by the medical staff, as Dr. Laurent Fiorina, Electrophysiologist at Institut Cardiovasculaire de Paris-Sud (France) and medical expert at Cardiologs confirms, “Cardiologs’ solution enabled us to be more efficient in our Holter analysis and to double diagnostic capacity. We can now deliver a faster ECG analysis with high confidence to our patients. The ease of use was a major reason for the team’s fast endorsement of this new ECG analysis device.”

Yann Fleureau, co-founder and CEO of Cardiologs, said, “We are extremely enthusiastic to partner with MicroPort CRM for the distribution of our unique technology in France. Its leading position in the Holter market combined with the expertise of its business teams, makes MicroPort CRM an ideal business partner to widely distribute Cardiologs’ solution to all the French cardiologists in hospitals as well as in outpatient medical offices.”

Benoît Clinchamps, President of MicroPort CRM, added, “We are very happy to launch this partnership with Cardiologs which perfectly reflects MicroPort CRM’s strategy: to offer new unique and innovative services that enable healthcare facilities and cardiologists to optimize their time, resources and improve patient diagnostics.”

France Schwarz, Director of Marketing Europe at Cardiologs added, “This agreement confirms our solution’s attractiveness and marks the first phase of our European marketing strategy.”

About Cardiologs
Cardiologs is a medical technology company committed to transforming cardiac diagnostics using medical-grade artificial intelligence and cloud technology. Developed in partnership with leading physicians, the Cardiologs ECG Analysis Solution empowers clinicians worldwide to deliver expert cardiac care faster and more efficiently. CE-Marked and FDA cleared for detection of 14 cardiac arrhythmias, the Cardiologs ECG Analysis Solution is built on a growing database of more than 5 million ECG recordings and is supported by a number of clinical publications.

For more information: https://cardiologs.com/

About MicroPort CRM
Pioneering physiological therapies in cardiac rhythm management. Driven by our expert R&D teams and state-of-the-art manufacturing facilities across the globe, MicroPort CRM conceives, designs and develops solutions for the management of cardiac rhythm disorders and heart failure. Headquartered in Paris, our precise technologies are manufactured in France, Italy, the Dominican Republic; and for the Chinese market, in China. .

For more information visit www.crm.microport.com

Clinical Study Shows Cardiologs’ AI Reduces The False Positive Burden Of Implantable Loop Recorders By Almost 70%

14.05.2020

Data presented at HRS 2020 shows Cardiologs’ AI-system successfully eliminates more than two-thirds of atrial fibrillation false positives from ILR reports, alleviating the clinical burden associated with remote monitoring

PARIS and BOSTON, May 14, 2020 /PRNewswire/ — Cardiologs, a global leader in artificial intelligence (AI) for cardiac diagnostics, today in partnership with the Valley Health System revealed the results of a clinical study that found the Cardiologs’ AI-based ECG analysis solution reduces by almost 70% the false positives of atrial fibrillation (AF) detected by implantable loop recorders (ILRs).

“Remote monitoring of ILRs has become an integral part of the modern cardiology practice. However, the deluge of data and the challenges in distinguishing real events from false positives can be time consuming and can siphon resources and attention from more pressing needs,” said cardiac electrophysiologist Dr. Rod Passman, Director of the Center for Arrhythmia Research and Jules J. Reingold Professor of Medicine (Cardiology) and Preventative Medicine at Northwestern University Feinberg School of Medicine in Chicago.

To address the issue, Cardiologs partnered with the Valley Health System to test an AI-based solution on a cohort of 348 patients who received an ILR for either Atrial Fibrillation (AF) or Cryptogenic Stroke (CS). The ILR ECG strips with 1,190 detected AF episodes were then uploaded into Cardiologs’ cloud-based platform and filtered through Cardiologs’ AI-based algorithm. The results show Cardiologs reduced the number of false positive episodes by 69.7% and 62% in the CS and known AF cohorts respectively – with a 1.7% and 0.6% corresponding false negative rate. The findings were first presented at the Heart Rhythm Society in May 2020 and will be published in HeartRhythm later this month.

“The use of ILRs has been a great addition to the long-term heart monitoring tool set. But the large amount of data associated with extended monitoring and specifically the high level of false positive AF detections have created a considerable burden in the management of ILR data. The Cardiologs’ AI solution offers remarkable promise to alleviating the heavy clinical burden associated with managing ILR patients,” said cardiac electrophysiologist Dr. Suneet Mittal, Director of Electrophysiology, Associate Chief of Cardiology, Medical Director of the Snyder Atrial Fibrillation Center, Director of Cardiac Research at Valley Health System, and lead investigator of the study.

“We are excited about the continuously expanding use of the Cardiologs AI platform,” said Yann Fleureau, Cardiologs’ Co-Founder and CEO. “It’s reaffirming to receive even more clinical validation – demonstrating the tremendous value and benefits that come with using the solution. We look forward to working with ILR users around the world in the months to come.”

About Cardiologs

Cardiologs is a medical technology company committed to transforming cardiac diagnostics using medical-grade artificial intelligence and cloud technology. Developed in partnership with leading physicians, the Cardiologs ECG Analysis Solution empowers clinicians worldwide to deliver expert cardiac care faster and more efficiently. CE-Marked and FDA cleared for detection of 14 cardiac arrhythmias, the Cardiologs ECG Analysis Solution is built on a growing database of more than 4 million ECG recordings and is supported by a number of clinical publications.

Andrea LePain
eMedia Junction
andrea@mediajuntion.com
617-275-8112

Cardiologs Announces Clinical Study to Monitor Cardiac Safety of COVID-19 Patients Via Smartwatches

22.04.2020

Trial will evaluate use of Cardiologs’ AI platform for QT interval analysis of ECG data from smartwatches in patients receiving hydroxychloroquine treatment

BOSTON, April 22, 2020 /PRNewswire/ — Cardiologs, a global leader in artificial intelligence (AI) for cardiac diagnostics, today announced the launch of a clinical study using the company’s ground-breaking AI-based solution to remotely monitor the cardiac safety of COVID-19 patients during hydroxychloroquine treatment via analysis of electrocardiogram (ECG) data gathered from smartwatches. Hydroxychloroquine therapy is associated with the risk of QT prolongation, a specific sign found on ECGs, which can lead to severe cardiac arrhythmias.

The trial will study patients with COVID-19 at the University Hospital of Marseille in France who are being treated with hydroxychloroquine and azithromycin, a drug combination currently being evaluated as a therapy for the coronavirus (SARS-CoV-2). These drugs can cause QT prolongation as a side effect, especially when used together, raising concerns about the risk of arrhythmic death.

“A significant QT prolongation can lead to ventricular arrhythmia and potentially deadly consequences,” explained Laurent Fiorina, a cardiologist at the Institut Cardiovasculaire Paris Sud (ICPS) and a medical expert at Cardiologs who initiated the project. “It is thus important to closely monitor the QT interval during this treatment.”

ECG assessment to monitor the QT interval is the current standard of care to ensure cardiac safety in clinical settings. With COVID-19, monitoring is especially challenging to implement because of the risk of contamination. It is also highly unlikely that it could be applied as a standard to a large population within a short period of time because of the strain on hospital resources.

“The objective of our study is to evaluate a new method for QT measurement using Cardiologs’ AI-based solution and ECG data collected via smartwatches,” added Professor Jean-Claude Deharo, head of the cardiac arrhythmia department at the University Hospital of Marseille and the principal investigator of the study. “Smartwatches are already used in the clinical setting but do not have validated QT analysis available. Combining these technologies will enable clinicians to overcome the practical limitations in the context of COVID-19 of the standard cardiac safety strategy that requires heavy patient interaction.”

Each patient in the study will receive a Withings Move ECG Watch linked to Cardiologs’ AI platform, which is already CE marked and FDA cleared for QT interval analysis and arrhythmia diagnostics. Throughout the 10-day course of treatment, daily ECG readings will be sent directly from the smartwatch to Cardiologs’ AI platform, where the data will be compared to the gold standard ECG measure and analyzed to assess drug-induced cardiotoxic risk as well as arrhythmic events.

“This study has implications for risk management of drug-induced cardiotoxicity, even beyond the current COVID-19 and hydroxychloroquine context,” said Professor Jag Singh, a cardiologist at Massachusetts General Hospital (MGH), Professor of Medicine at Harvard Medical School, and a scientific advisor to Cardiologs. “Personal ECG sensors could potentially find a role in the management of these patients, but also add value in other routine clinical care, since over 300 commonly used drugs may have similar QT-prolongation risks as hydroxychloroquine.”

Cardiologs is exploring the possibility of additional studies involving different wearable ECG monitors with partners in the United States.

About Cardiologs

Cardiologs is a medical technology company on a mission to democratize expert cardiac care through medical-grade artificial intelligence. Developed in partnership with leading institutions, the Cardiologs ECG Analysis Platform empowers clinicians worldwide to deliver cardiac diagnostics faster and more efficiently. CE-Marked and FDA cleared for arrhythmia diagnostics, device agnostic, the Cardiologs ECG Analysis Platform is built on a growing database of more than 3 million ECG recordings and is supported by a number of clinical publications.

Media Contact(s)
Andrea LePain
eMedia Junction
andrea@emediajunction.com
617-894-1153

Cardiologs Raises $15 Million in Series A Funding Led by Alven

10.01.2020

Funding will accelerate adoption of the company’s breakthrough AI-based heart disease diagnostic solution by supporting physicians with unprecedented EKG data analysis and reporting capabilities

PARIS and BOSTON, Jan. 10, 2020 /PRNewswire/ — Cardiologs, a global leader in artificial intelligence (AI) cardiology diagnostics, today announced that it has secured  $15 million in Series A funding, bringing the total capital raised since Cardiologs’ inception to more than $25 million. The financing round was led by Alven, a leading venture capital firm in Paris known for its impressive track record of investing in and expanding into the U.S. successful technology startups founded by French entrepreneurs.  Previous backers Bpifrance, ISAI, Kurma Diagnostics, Idinvest Partners and Paris Saclay Seed Fund also participated in the round.

“We have developed a new category of heart disease diagnostic products powered by AI that promise to revolutionize healthcare by delivering accurate, cost-effective and timely expert-level diagnostics,” said Yann Fleureau, co-founder and CEO of Cardiologs. “We are excited to work with our new partners at Alven and other earlier investors as we enter the next critical stage of our evolution as a company.”

Building off of strong revenues growth in 2019, notably in the U.S., Cardiologs intends to use the new funding to immediately grow its market share by ramping up sales and marketing efforts across North America and Europe. The money will also be used to further build the pioneering technology platform with new integrations and expanded applications.

“With its unique software built around a cutting-edge technology that blends deep learning with diagnostic clinical science and workflow, Cardiologs is already improving a traditionally manually-processed industry to generate substantial improvements in the speed, cost and accuracy of diagnostics.” says François Meteyer, Partner at Alven. “This will be a key differentiator to build a new AI-based category in the cardiology field, democratizing the access to instant, reliable and affordable expertise for every patient, every test, everywhere. We’re excited to support this European-rooted global business in its development .”

“We’ve been impressed by Cardiologs’ achievements since the seed round and we’re very excited to invest again and help build a category leader in the medical diagnostic industry,” commented Jonathan Userovici, Investment Manager at Idinvest Partners, an opinion shared by Jean-Patrice Anciaux, Investment Director at Bpifrance Digital Venture and also an early investor in the company.

Cardiologs’ ability to quickly detect and diagnose heart conditions as effectively as the world’s top human cardiologists has promising implications. The AI model, which was trained on more than 1.4 million ECG recordings, is capable of spotting more than 100 different cardiac abnormalities and is FDA- cleared for all clinically-relevant arrhythmias. In addition, the system can interpret data from a broad range of cardiac monitoring devices and generate a report within minutes, enabling faster and more efficient diagnosis for patients.

Founded in Europe in 2014, Cardiologs has grown into a global brand and is already assisting clinicians across four continents with identifying heart rhythm abnormalities. The company continues to grow due to strong demand for accurate, cost-effective and timely heart disease diagnostics in the global healthcare market.

About Cardiologs
Cardiologs is a medical technology company committed to transforming cardiac diagnostics using medical-grade artificial intelligence and cloud technology.  Developed in partnership with leading physicians, the Cardiologs ECG Analysis Solution empowers clinicians worldwide to deliver expert cardiac care faster and more efficiently.  CE-Marked and FDA cleared for detection of 14 cardiac arrhythmias, the Cardiologs ECG Analysis Solution is built on a growing database of more than 1.4 million ECG recordings and is supported by a number of clinical publications.

About Alven
Alven is an independent venture capital fund with over $500 million in assets under management and nearly 130 companies financed in 20 years. Alven’s mission is to support the long-term success of outstanding European digital & technology entrepreneurs.
Amongst the investments made by Alven are Algolia, Dataiku, Drivy (bought by Getaround), Happn, Captain Train (Trainline/KKR), Bime Analytics (Zendesk), Webhelp, Peopledoc, Sqreen, Meero, Qonto, or MeilleursAgents (recently bought by Axel Springer).
Find out more at www.alven.co

About Idinvest
Idinvest Partners is a leading European mid-market private equity firm. With €8bn under management, the firm has developed several areas of expertise including innovative startup venture capital transactions; mid-market private debt, i.e. senior and subordinated debt; primary and secondary investment and private equity advisory services. Founded in 1997, Idinvest Partners used to belong to the Allianz Group until 2010, when it branched out as an independent firm. In January 2018, Idinvest Partners became a subsidiary of Eurazeo, a leading global investment company, with a diversified portfolio of €17.7bn in assets under management, including nearly €11.6bn from investment partners, invested in nearly 400 companies.

About Bpifrance and Bpifrance Digital Ventures
Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy.) to help entrepreneurs meet their challenges (innovation, export…).
Bpifrance Digital Venture is the VC team within Bpifrance, dedicated to digital and tech companies aiming to become global leader on their market. It focuses on Seed and Series A/B stages. With €650 million under management, the team backed nearly 80 companies and had 10 exits since 2011. Amongst the investments made by Bpifrance Digital Venture team are Teads (bought by Altice), Talentsoft, Netatmo (Legrand), Meilleurs Agents (Axel Springer), Balyo, Manomano, Evaneos, Openclassrooms, GitGuardian, Strapi, Numworks.

For more information, please visit: www.bpifrance.fr and presse.bpifrance.fr 
Follow us on Twitter: @Bpifrance – @BpifranceDV – @BpifrancePresse

About Kurma Partners
Kurma Partners is a key European player in the financing of innovation in healthcare and biotechnology, notably through Kurma Biofund I and II, Kurma Diagnostics and strategic partnerships with prestigious European research and medical institutions.
www.kurmapartners.com

About ISAI
Launched in 2010, ISAI is the Tech Entrepreneurs’ Fund and brings together a community of over 250 entrepreneurs around the world.
Nearly 200 successful entrepreneurs, who have invested in ISAI funds, and more than 50 ISAI-backed start-up co-founders share the collective ambition of co-writing great entrepreneurial stories. ISAI invests in differentiated projects run by ambitious teams that it selects rigorously and actively supports. ISAI Gestion, an investment management company approved by the AMF, with over €400 million under management, aims to finance and support high potential Tech companies, at the seed/post-seed stage (venture capital, ticket from €150k ticket to €2m with participations in successive rounds) or when they have already reached the break-even stage (Tech Growth/LBO, tickets from €5m to €30m).
More information on www.isai.fr/en

Media Contact 
Andrea LePain
andrea@emediajunction.com 
eMedia Junction
617-275-8112

SOURCE Cardiologs

Related Links

https://cardiologs.com/